Anshika Jain, Ph.D., Joins American Gene Technologies® as Principal Scientist
In this role, Dr. Jain will lead the translational studies for the American Gene™ HIV cure clinical trial, developing scientific plans and overseeing the research. Specifically, she will be responsible for identifying the biomarkers, developing and validating assays, managing vendors for outsourced projects, analyzing the scientific data, and working with the team to understand the patient data and the clinical outcome of the HIV trials.
Previously, Dr. Jain was a postdoctoral fellow at the National Institutes of Health (NIH), where she was responsible for leading several projects. One of the more exciting projects she led involved studying the biochemistry of HIV proteins and identifying unidentified metal factors present within these proteins. Her scientific expertise coupled with my unique skills and experience gained while a Scientific Program Analyst at NIH, makes me a good fit for my current role at American Gene™.
“Anshika comes to American Gene with a range of skills that will be fundamental to our success as we move our HIV program into the next phase. Her strengths include translation, academic and leadership skills developed at USC, NIH, and experience working with industry as part of the RADx program,” said Dr. Jeff Boyle, Chief Science Officer at American Gene™. “These talents will be used as we complete our Phase I study where Anshika will be an integral leader for the translation team in applying the insights gained for success of our next Phase I/II study.”
About American Gene Technologies®
American Gene Technologies® is a gene therapy company with a proprietary gene-delivery platform for rapid development of gene therapies to cure infectious diseases, cancers, and inherited disorders. Its mission is to transform people’s lives through genetic medicines that rid the body of disease. American Gene Technologies® has been granted numerous patents for the technology used to make AGT103-T and for its unique immuno-oncology approach to stimulate gamma-delta (γδ) T cells to destroy a variety of solid tumors. The company has developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. The company’s treatment for PKU has been granted Orphan Drug Designation by the Food and Drug Administration (FDA), and it is expected to reach the clinic in 2023.
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
